Medical management of ankylosing spondylitis

Alexander A. Khalessi, Bryan C. Oh, Michael Y. Wang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the fol1owing literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor-α blockade therapy. Response should occur within 6-12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.

Original languageEnglish
Article numberE4
JournalNeurosurgical Focus
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Ankylosing Spondylitis
Therapeutics
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmaceutical Preparations
Adrenal Cortex Hormones
Tuberculosis
Radiotherapy
Tumor Necrosis Factor-alpha
Guidelines
Pain

Keywords

  • Ankylosing spondylitis
  • Medical management
  • Nonsteroidal antiinflammatory drug
  • Tumor necrosis factor-α blockade

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Medical management of ankylosing spondylitis. / Khalessi, Alexander A.; Oh, Bryan C.; Wang, Michael Y.

In: Neurosurgical Focus, Vol. 24, No. 1, E4, 01.01.2008.

Research output: Contribution to journalArticle

Khalessi, Alexander A. ; Oh, Bryan C. ; Wang, Michael Y. / Medical management of ankylosing spondylitis. In: Neurosurgical Focus. 2008 ; Vol. 24, No. 1.
@article{d8b7681dfd8a48fda629cb7f890e7af8,
title = "Medical management of ankylosing spondylitis",
abstract = "In the fol1owing literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor-α blockade therapy. Response should occur within 6-12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.",
keywords = "Ankylosing spondylitis, Medical management, Nonsteroidal antiinflammatory drug, Tumor necrosis factor-α blockade",
author = "Khalessi, {Alexander A.} and Oh, {Bryan C.} and Wang, {Michael Y.}",
year = "2008",
month = "1",
day = "1",
doi = "10.3171/FOC/2008/24/1/E4",
language = "English",
volume = "24",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Medical management of ankylosing spondylitis

AU - Khalessi, Alexander A.

AU - Oh, Bryan C.

AU - Wang, Michael Y.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - In the fol1owing literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor-α blockade therapy. Response should occur within 6-12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.

AB - In the fol1owing literature review the authors consider the available evidence for the medical management of patients with ankylosing spondylitis (AS), and they critically assess current treatment guidelines. Medical therapy for axial disease in AS emphasizes improvement in patients' pain and overall function. First-line treatments include individualized physical therapy and nonsteroidal antiinflammatory drugs (NSAIDs) in conjunction with gastroprotective therapy. After an adequate trial of therapy with two NSAIDs exceeding 3 months or limited by medication toxicity, the patient may undergo tumor necrosis factor-α blockade therapy. Response should occur within 6-12 weeks, and patients must undergo tuberculosis screening. Evidence does not currently support the use of disease modifying antirheumatic drugs, corticosteroids, or radiotherapy in AS.

KW - Ankylosing spondylitis

KW - Medical management

KW - Nonsteroidal antiinflammatory drug

KW - Tumor necrosis factor-α blockade

UR - http://www.scopus.com/inward/record.url?scp=41949096845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949096845&partnerID=8YFLogxK

U2 - 10.3171/FOC/2008/24/1/E4

DO - 10.3171/FOC/2008/24/1/E4

M3 - Article

C2 - 18290742

AN - SCOPUS:41949096845

VL - 24

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 1

M1 - E4

ER -